Evidence map›Paper›PMID 38481231›Full record

ArticleHealth and quality of life outcomes2024

Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.

Jyoti Dixit, Nidhi Gupta, Amal Kataki, Partha Roy, Nikita Mehra, Lalit Kumar, Ashish Singh, Pankaj Malhotra, Dharna Gupta, Aarti Goyal and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
41.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Jyoti DixitDepartment of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Nidhi GuptaDepartment of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.
Amal KatakiDr. B. Booroah Cancer Institute, Guwahati, Assam, India.
Partha RoyDr. B. Booroah Cancer Institute, Guwahati, Assam, India.
Nikita MehraDepartment of Medical Oncology, Adyar Cancer Institute, Chennai, Tamil Nadu, India.
Lalit KumarDepartment of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Ashish SinghDepartment of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India.
Pankaj MalhotraDepartment of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Dharna GuptaDepartment of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Aarti GoyalDepartment of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Kavitha RajsekarDepartment of Health Research, Ministry of Health and Family Welfare, New Delhi, India.
Manjunath Nookala KrishnamurthyDepartment of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
Sudeep GuptaDepartment of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
Shankar PrinjaDepartment of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. shankarprinja@gmail.com.
Post Graduate Institute of Medical Education and Research · INBhubaneswar Borooah Cancer Institute · INTata Memorial Hospital · INAll India Institute of Medical Sciences · INCancer Institute (WIA) · INChristian Medical College, Vellore · INGovernment Medical College and Hospital · INMinistry of Health and Family Welfare · IN

Funding

Department of Health Research, Ministry of Health and Family Welfare, New Delhi F.No.T.11011/02/2017-HR/3100291.
6 · The paper itself

Abstract

backgroundCancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants.

methodsData were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L). Multiple linear regression was used to determine the association between HRQoL and various socio-demographic as well as clinical characteristics.

resultsMajority outpatients (78.4%) and inpatients (81.2%) had solid cancers. The disease was found to be more prevalent among outpatients (37.5%) and inpatients (40.5%) aged 45-60 years and females (49.3-58.3%). Most patients were found to be in stage III (40-40.6%) or stage IV (29.4-37.3%) at the time of recruitment. The mean EQ-5D-5 L utility score was significantly higher among outpatients [0.630 (95% CI: 0.623, 0.637)] as compared to inpatients [0.553 (95% CI: 0.539, 0.567)]. The HRQoL decreased with advancing cancer stage among both inpatients and outpatients, respectively [stage IV: (0.516 & 0.557); stage III (0.609 & 0.689); stage II (0.677 & 0.713); stage I (0.638 & 0.748), p value < 0.001]. The outpatients on hormone therapy (B = 0.076) showed significantly better HRQoL in comparison to patients on chemotherapy. However, palliative care (B=-0.137) and surgery (B=-0.110) were found to be associated with significantly with poorer HRQoL paralleled to chemotherapy. The utility scores among outpatients ranged from 0.305 (bone cancer) to 0.782 (Leukemia). Among hospitalized cases, the utility score was lowest for multiple myeloma (0.255) and highest for testicular cancer (0.771).

conclusionOlder age, lower educational status, chemotherapy, palliative care and surgery, advanced cancer stage and progressive disease were associated with poor HRQoL. Our study findings will be useful in optimising patient care, formulating individualized treatment plan, improving compliance and follow-up.

Indexed as

Multiple MyelomaTesticular NeoplasmsEducational StatusFemaleHumansMaleQuality of LifeSurveys and QuestionnairesAdverse effectsCancerCancer siteHealth-related quality of lifeIndiaTreatment responseType of treatmentUtility scores

Identifiers

PMID38481231
PMCPMC10938809
OpenAlexW4392749129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.